Sanaria Inc.: Malaria trials

The registry lists 28 Malaria studies with Sanaria Inc. as lead sponsor. 3 are open to participants now and 3 have results posted.

Phase 1 22Phase 2 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliRecruitingNCT07675785Phase 2
• Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsRecruitingNCT07385287Phase 2
• Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingNCT06862453Phase 1
• A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMITerminatedNCT05604521Phase 1Results posted
• PfSPZ Vaccine Trial in Malian ChildrenCompletedNCT04940130Phase 2Results posted
• Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted MalariaCompletedNCT03503058Phase 2Results posted
• Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina FasoCompletedNCT06652737Phase 1
• Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve AdultsCompletedNCT04966871Phase 1
• Regimen Optimization Trial of PfSPZ Vaccine in Equatorial GuineaCompletedNCT03590340Phase 1
• Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese ChildrenCompletedNCT03521973Phase 2
• Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian AdultsCompletedNCT03420053Phase 1
• Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch VolunteersCompletedNCT03163121Phase 1
• Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.CompletedNCT02859350Phase 1
• Sequential Optimization of Dose and Schedule of PfSPZ VaccineCompletedNCT02704533Phase 1
• Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in KenyaCompletedNCT02687373Phase 1/2
• Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and InfantsCompletedNCT02613520Phase 1
• PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve AdultsCompletedNCT02601716Phase 2
• Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean AdultsCompletedNCT02418962Phase 1
• Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ ChallengeCompletedNCT02237586Phase 1
• A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of DosesCompletedNCT02215707Phase 1
• Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian AdultsCompletedNCT02132299Phase 1
• Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under ChemoprophylaxisCompletedNCT02115516Phase 1
• Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune AdultsCompletedNCT01771848Phase 1
• Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine ProphylaxisCompletedNCT01728701Phase 1
• Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune AdultsCompletedNCT01624961Phase 1
• Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian AdultsCompletedNCT01540903Phase 1
• Experimental Human Malaria Infection by PfSPZCompletedNCT01086917Phase 1
• Clinical Trial of the PfSPZ VaccineCompletedNCT01001650Phase 1